CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 45 enrolled
Drug / intervention
Nivolumab (Cohort A) +5 moredrug
Likely dose
Nivolumab (Cohort A) 360 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04787991
NCT04787991Phase 1Completed
CompareCT.gov

A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)

Cancer Insight, LLC·interventional·Posted Mar 9, 2021·Updated Oct 30, 2025

In Brief

A Phase 1 clinical trial evaluating Nivolumab (Cohort A), Ipilimumab (Cohort A, B and C), and 4 other interventions for Metastatic Pancreatic Adenocarcinoma. Completed, enrolled 45 participants across 6 sites.

Detailed Summary

This trial is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of first-line chemo-immunotherapy combinations in participants with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Pancreatic Adenocarcinoma
CountriesUnited States
CollaboratorsBristol-Myers Squibb, Cancer Research Institute, New York City, Akamis Bio

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedMar 9, 2021
Enrollment StartAug 9, 2021
Primary CompletionNov 12, 2024
Study CompletionJul 31, 2025
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 5.3 years ago

Interventions

Nivolumab (Cohort A)drug

Nivolumab will be administered intravenously at 360 mg every 3 weeks for up to 2 years.

Ipilimumab (Cohort A, B and C)drug

For Cohort A and B, ipilimumab will be administered intravenously at 1mg/kg every 6 weeks for up to 2 cycles. For Cohort C, ipilimumab will be administered intravenously at 1mg/kg on C2D1 and C4D1.

Hydroxychloroquine (HCQ) (Cohort B)drug

Hydroxychloroquine will be administered orally daily for up to 2 years.

Nab-paclitaxel (nP) (Cohort A, B and C)drug

Nab-paclitaxel will be administered intravenously at 125 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.

Gemcitabine (gem) (Cohort A, B and C)drug

Gemcitabine will be administered intravenously at 1000 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.

NG350A (Cohort C)drug

NG-350A will be administered intravenously on Cycle 1 Days 15 (1e12 viral particles), 17 (3e12 viral particles), and 19 (3e12 viral particles).